| Biomedical products refers to the micro-organisms, | | | | Biomedical Company Limited, ABON (Hangzhou) Co., |
| parasites, animal toxins, biological tissue as starting | | | | Ltd., of Lanzhou Biological Technology Development |
| material, purified by a biological process or technical | | | | Co., Ltd., Shanghai Branch of China and Bioengineering |
| preparation, technology and analysis of biological | | | | Co., Ltd. Liaoning, and Sichuan Yuanda Cheng Kung |
| control of the quality of intermediate products and | | | | University Biological Pharmaceutical Co., Shu Yang |
| finished products made from bio-active agents, such | | | | China biomedical companies, among the top 10 |
| as plague (bacteria) vaccine, toxin, toxoid, immune | | | | exports, up 59.66 percent share. |
| serum, blood products, immunoglobulin, antigen, | | | | Market In 2009, total exports to China Biological |
| allergen, and cytokines. | | | | Medicine 126 countries and regions, Asia is the main |
| In the current customs Export Tariff, it is also no | | | | export market share as high as 59.57 percent. In |
| uniform, clear tariff biomedicine, genetic engineering, | | | | 2009, China's top ten trading partners, exports of |
| biological medicine, such as vaccines, monoclonal | | | | bio-medicine followed by India, the United States, |
| antibodies, interferon and blood products and other | | | | China, Hong Kong, Canada, Egypt, Ethiopia, Vietnam, |
| imports and exports, usually through under the | | | | Indonesia, Thailand and Pakistan, the proportion |
| customs tariff 3002. Therefore, data on national | | | | reached 77.99%, of which only the Indian market |
| statistics, biomedical difficult to fully reflect China's | | | | share as high as 34.66%. |
| actual situation of import and export of biological | | | | Varieties in 2009, China's human vaccine exports |
| medicine. No doubt, China will show strong growth in | | | | 19,157,600 U.S. dollars, up 19.71 percent, were |
| import and export of bio-medicine momentum. | | | | exported to 35 countries and regions, Oceania and |
| 2009, China's import and export amount of biomedical | | | | North America did not export records, the main |
| 887 million U.S. dollars, up 44.35%, of which exports | | | | export markets India, Pakistan, South Korea, Malawi |
| grew 53.16 percent, exports grew 19.71% vaccine | | | | and Thailand, up 84.63 percent share, of which India's |
| Import and export of China is facing biomedical | | | | share is only as high as 67.39%. |
| development of better opportunities, strong | | | | 20 enterprises in China engaged in export of human |
| government support, China's bio-pharmaceutical | | | | vaccines, Chengdu Institute of Biological Products, |
| industry has made great progress, and international | | | | Biological Co., Ltd. Liaoning Cheng Kung University, |
| bio-pharmaceutical industry are becoming increasingly | | | | Changchun Institute of Biological Products Import |
| close, in keeping Biomedical Import Substantial | | | | & Export Department, Shenzhen City Industrial |
| growth, a number of biomedical exports are growing | | | | Development Co., Ltd. Main Gao, Changchun Chang |
| steadily. | | | | Sheng Biotechnology Co., Ltd. rank in 2009 exports |
| 2009, China's import and export amount of biomedical | | | | of vaccines for human use the top five, up 87.19 |
| 887 million U.S. dollars, up 44.35 percent. Among them, | | | | percent share, of which only the proportion of the |
| the exports 87,175,000 US dollars, up 53.16 percent; | | | | Chengdu Institute of Biological Products as high as |
| imports amounted to 800 million US dollars, up | | | | 45.92 percent. |
| 43.35%, imports and exports showed a dramatic | | | | The new century, with SARS, H5N1, H1N1 and other |
| upward trend, the development of potentially very | | | | viruses turns raging, all kinds of Epidemic The trend |
| strong. At present, China Bio Pharmaceutical Industry | | | | was spreading around the world, making a substantial |
| Has been developed to more than 500 biological | | | | increase in demand for the vaccine market, according |
| pharmaceutical industry more than 40 billion yuan | | | | to forecasts, the global vaccine market sales will |
| sales income, but lower than the global | | | | increase rate of 18%, 2011, the global vaccine market |
| bio-pharmaceutical industry in the pharmaceutical | | | | sales will grow to 30 billion U.S. dollars. |
| industry in the proportion of biomedical industry in | | | | Inexpensive vaccine as China, in Asia, Africa, popular |
| China also shows a very large room for development. | | | | market and maintain the momentum of rapid growth. |
| Can be expected: in 2010 China's import and export | | | | Chengdu Institute of Biological Products Over the |
| of bio-medicine will continue to maintain high growth. | | | | years, successfully passed the review of the Indian |
| Export Asia is the main market, a major | | | | drug regulatory departments, its own intellectual |
| breakthrough in vaccine | | | | property rights of JE vaccine into the government |
| Company in 2009, engaged in biomedical Drugs | | | | procurement system in India, marking China's |
| Exports total 135 enterprises, exports of 100 million | | | | biomedical industry has been greatly improved, but In |
| or more enterprises have 20, the Chengdu Institute | | | | addition to outside of Chengdu Institute of Biological |
| of Biological Products, Ed Inspection Technologies Co., | | | | Products, no other domestic enterprises to enter the |
| Ltd., Shanghai RAAS Blood Products Co., Ltd., Hualan | | | | foreign government procurement area. |
| Biological Engineering Co., Ltd. four Chuanke Lun | | | | |